October 2025
1. GUTIERREZ J, Ayub A, Piva SE, Shirk JD, et al
   IP11-07 A 3D Tumor Map for the Surgical Management of Bladder Cancer: Feasibility and Preliminary Analysis: Erratum.
   J Urol. 2025;214:458.
   

   >> Share

   
   June 2025
2. MOYER JA, Durant AM, Nguyen MV, Mi L, et al
   Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
   J Urol. 2025 Jun 26:101097JU0000000000004658. doi: 10.1097/JU.0000000000004658.
   

   >> Share

   
   
3. KOTI M, Michaud E, Siemens DR
   Non-modifiable drivers of BCG response: Considerations of age, sex and chronic inflammation for the management of non-muscle invasive bladder cancer.
   J Urol. 2025 Jun 10:101097JU0000000000004632. doi: 10.1097/JU.0000000000004632.
   

   >> Share

   
   
4. VENKATRAMANI V, Reis IM, Gonzalgo ML, Swain S, et al
   Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.
   J Urol. 2025;213:684-692.
   

   >> Share

   
   April 2025
5. HUSSEIN AA, Mahmood AW, Ahmad A, Houenstein H, et al
   Do Prophylactic Antibiotics Decrease the Rate of Urinary Tract Infections after Robot-Assisted Radical Cystectomy? A Randomized Controlled Trial.
   J Urol. 2025 Apr 25:101097JU0000000000004586. doi: 10.1097/JU.0000000000004586.
   

   >> Share

   
   
6. LOTAN Y, Li R, Chang SS
   AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated Non-muscle Invasive Bladder Cancer.
   J Urol. 2025 Apr 16:101097JU0000000000004541. doi: 10.1097/JU.0000000000004541.
   

   >> Share

   
   
7. ZHONG Y, Wei J, Jiang R
   Letter: Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage of 2 Grading Systems.
   J Urol. 2025 Apr 15:101097JU0000000000004555. doi: 10.1097/JU.0000000000004555.
   

   >> Share

   
   
8. TALLMAN JE, Vertosick EA, Alam SM, Baky FJ, et al
   Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted Radical Cystectomy With Intracorporeal Ileal Conduit.
   J Urol. 2025;213:437-446.
   

   >> Share

   
   
9. AHMED ME, Andrews JR, Mahmoud AM, Reitano G, et al
   Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes.
   J Urol. 2025;213:447-454.
   

   >> Share

   
   March 2025
10. KAMAT AM, van Rhijn BWG, Van der Kwast T
    Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage Of Two Grading Systems.
    J Urol. 2025 Mar 25:101097JU0000000000004542. doi: 10.1097/JU.0000000000004542.
    

    >> Share

    
    
11. STOVER AM, Mueller D, Carda-Auten J, Hilton A, et al
    Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial.
    J Urol. 2025 Mar 6:101097JU0000000000004511. doi: 10.1097/JU.0000000000004511.
    

    >> Share

    
    February 2025
12. KHENE ZE, Bhanvadia R, Attia S, Ito W, et al
    Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naive Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2025 Feb 10:101097JU0000000000004472. doi: 10.1097/JU.0000000000004472.
    

    >> Share

    
    
13. HOLZBEIERLEIN JM
    Reply: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2025 Feb 10:101097JU0000000000004452. doi: 10.1097/JU.0000000000004452.
    

    >> Share

    
    
14. HEER R, Boaz RJ, Tan WS, Gravestock P, et al
    Letter: Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2025 Feb 7:101097JU0000000000004431. doi: 10.1097/JU.0000000000004431.
    

    >> Share

    
    
15. SHARMA V, Fadel A, Tollefson MK, Psutka SP, et al
    Artificial Intelligence-Based Assessment of Preoperative Body Composition Is Associated With Early Complications After Radical Cystectomy.
    J Urol. 2025;213:228-237.
    

    >> Share

    
    December 2024
16. 
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment: Erratum.
    J Urol. 2024;212:936.
    

    >> Share

    
    November 2024
17. RAMOS P, Bras JP, Dias C, Bessa-Goncalves M, et al
    Uromonitor(R): Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2024 Nov 19:101097JU0000000000004335. doi: 10.1097/JU.0000000000004335.
    

    >> Share

    
    
18. PIETZAK E, Anderson CB
    What is the Standard of Care For Multifocal Low-Grade Bladder Cancer?
    J Urol. 2024 Nov 18:101097JU0000000000004316. doi: 10.1097/JU.0000000000004316.
    

    >> Share

    
    October 2024
19. VILLEGAS E, Lajkosz K, Din S, Kuk C, et al
    Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.
    J Urol. 2024 Oct 29:101097JU0000000000004305. doi: 10.1097/JU.0000000000004305.
    

    >> Share

    
    
20. PRASAD SM, Shishkov D, Mihaylov NV, Khuskivadze A, et al
    Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
    J Urol. 2024 Oct 24:101097JU0000000000004296. doi: 10.1097/JU.0000000000004296.
    

    >> Share

    
    
21. LOTAN Y, Krishna V, Abuzeid WM, Launer B, et al
    Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort.
    J Urol. 2024 Oct 9:101097JU0000000000004278. doi: 10.1097/JU.0000000000004278.
    

    >> Share

    
    
22. CHRISTOPH SOERENSEN SJ, Schmidt B, Thomas IC, Montez-Rath ME, et al
    An Automated Electronic Health Record Score to Estimate Length of Stay and Readmission in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    J Urol. 2024 Oct 2:101097JU0000000000004262. doi: 10.1097/JU.0000000000004262.
    

    >> Share

    
    
23. 
    Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy? Erratum.
    J Urol. 2024;212:641.
    

    >> Share

    
    
24. PASSARELLI R, Ghodoussipour S, Packiam VT
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024;212:622-623.
    

    >> Share

    
    September 2024
25. PETERSEN E, Holt S, Browning A, Cavanaugh D, et al
    Characterizing Psychological Resources and Resilience in Patients With Bladder Cancer: Associations With Frailty and Quality of Life.
    J Urol. 2024 Sep 30:101097JU0000000000004257. doi: 10.1097/JU.0000000000004257.
    

    >> Share

    
    
26. WU Y, Zhang Z
    Letter: The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2024 Sep 27:101097JU0000000000004248. doi: 10.1097/JU.0000000000004248.
    

    >> Share

    
    
27. GHOREIFI A, Daneshmand S
    Technical Considerations to Minimize False-Positive Findings in Blue Light Cystoscopy for Non-muscle-invasive Bladder Cancer.
    J Urol. 2024 Sep 16:101097JU0000000000004250. doi: 10.1097/JU.0000000000004250.
    

    >> Share

    
    
28. ANDERSON CB
    What Is the Future of Cystoscopy for Detecting Urothelial Carcinoma?
    J Urol. 2024;212:399-400.
    

    >> Share

    
    July 2024
29. HALSTUCH D, Kool R, Marcq G, Breau RH, et al
    The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder Cancer.
    J Urol. 2024 Jul 25:101097JU0000000000004160. doi: 10.1097/JU.0000000000004160.
    

    >> Share

    
    
30. CHANG SS
    Urological Oncology: Bladder, Penis, and Urethra Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Jul 25:101097JU0000000000004120. doi: 10.1097/JU.0000000000004120.
    

    >> Share

    
    
31. DINNEY CPN, Narayan VM
    Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jul 5:101097JU0000000000004128. doi: 10.1097/JU.0000000000004128.
    

    >> Share

    
    
32. LAZAROVICH A, Dahmen AS, Modi PK, Agarawal PK, et al
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024;212:236-237.
    

    >> Share

    
    
33. LOTAN Y, Daneshmand S, Shore N, Black P, et al
    A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
    J Urol. 2024;212:41-51.
    

    >> Share

    
    
34. PATEL SH, Gabrielson AT, Chan S, Schwartz D, et al
    A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
    J Urol. 2024;212:95-103.
    

    >> Share

    
    June 2024
35. LINSCOTT J, Li R
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jun 24:101097JU0000000000004122. doi: 10.1097/JU.0000000000004122.
    

    >> Share

    
    
36. MEEKS JJ
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jun 19:101097JU0000000000004097. doi: 10.1097/JU.0000000000004097.
    

    >> Share

    
    
37. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Jun 17:101097JU0000000000004092. doi: 10.1097/JU.0000000000004092.
    

    >> Share

    
    
38. KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
    The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2024 Jun 7:101097JU0000000000004070. doi: 10.1097/JU.0000000000004070.
    

    >> Share

    
    
39. DJALADAT H, Ghoreifi A, Tejura T, Miranda G, et al
    Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
    J Urol. 2024;211:743-753.
    

    >> Share

    
    May 2024
40. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 May 17:101097JU0000000000004018. doi: 10.1097/JU.0000000000004018.
    

    >> Share

    
    
41. NARAYAN VM, Boorjian SA, Alemozaffar M, Konety BR, et al
    Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
    J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020.
    

    >> Share

    
    
42. KARABURUN MC, Kuz ED, Akpinar C, Obaid K, et al
    Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy?
    J Urol. 2024 May 1:101097JU0000000000003990. doi: 10.1097/JU.0000000000003990.
    

    >> Share

    
    April 2024
43. HOLZBEIERLEIN J, Bixler BR, Buckley DI, Chang SS, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO GUIDELINE (2017; Amended 2020, 2024).
    J Urol. 2024 Apr 25:101097JU0000000000003981. doi: 10.1097/JU.0000000000003981.
    

    >> Share

    
    
44. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Apr 22:101097JU0000000000003900. doi: 10.1097/JU.0000000000003900.
    

    >> Share

    
    
45. KAY H, Silver SN, Smith AB, Basak R, et al
    Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study.
    J Urol. 2024 Apr 11:101097JU0000000000003964. doi: 10.1097/JU.0000000000003964.
    

    >> Share

    
    
46. ALLORY Y, Culine S, Krucker C, Fontugne J, et al
    Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
    J Urol. 2024;211:564-574.
    

    >> Share

    
    March 2024
47. MONTORSI F, Moschini M, Gandaglia G, Briganti A, et al
    Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATL
    J Urol. 2024;211:482-483.
    

    >> Share

    
    
48. GILL IS, Desai MM, Cacciamani GE, Khandekar A, et al
    Robotic Radical Cystectomy for Bladder Cancer: The Way Forward.
    J Urol. 2024;211:476-480.
    

    >> Share

    
    
49. BOCHNER BH, Kamat AM, Bivalacqua TJ
    Open vs Robotic Cystectomy: Case Closed?
    J Urol. 2024;211:473-475.
    

    >> Share

    
    February 2024
50. WEISS K, Abimbola O, Mueller D, Basak R, et al
    Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery.
    J Urol. 2024;211:266-275.
    

    >> Share

    
    
51. KAY H, Matulewicz RS, Bjurlin MA
    Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials.
    J Urol. 2024 Feb 1:101097JU0000000000003853. doi: 10.1097/JU.0000000000003853.
    

    >> Share

    
    January 2024
52. HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
    

    >> Share

    
    November 2023
53. SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
    Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
    J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
    

    >> Share

    
    September 2023
54. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    

    >> Share

    
    
55. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    

    >> Share

    
    
56. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    

    >> Share

    
    
57. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    

    >> Share

    
    
58. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
    J Urol. 2023;210:408.
    

    >> Share

    
    
59. WONG N, So WZ, Tiong HY
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
    J Urol. 2023;210:407-408.
    

    >> Share

    
    August 2023
60. PRASAD SM, Huang WC, Shore ND, Hu B, et al
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
    

    >> Share

    
    
61. TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
    International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
    J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
    

    >> Share

    
    July 2023
62. JI J, Lai CH, Wang Q, Hu H, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
    J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
    

    >> Share

    
    
63. 
    PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2023;210:222.
    

    >> Share

    
    June 2023
64. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    

    >> Share

    
    
65. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    

    >> Share

    
    May 2023
66. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
    

    >> Share

    
    
67. TYSON MD, Morris D, Palou J, Rodriguez O, et al
    Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
    J Urol. 2023;209:890-900.
    

    >> Share

    
    
68. GILBERT SM
    Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not.
    J Urol. 2023;209:833-835.
    

    >> Share

    
    
69. GHOREIFI A, Ladi-Seyedian SS, Piatti P, Chew YC, et al
    A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.
    J Urol. 2023;209:854-862.
    

    >> Share

    
    
70. KIRK PS, Lotan Y, Zargar H, Fairey AS, et al
    Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
    J Urol. 2023;209:882-889.
    

    >> Share

    
    
71. YIP W, Sjoberg DD, Nogueira LM, Tracey AT, et al
    Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:863-871.
    

    >> Share

    
    
72. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial.
    J Urol. 2023;209:901-910.
    

    >> Share

    
    
73. LABBATE C, Woldu S, Murray K, Rose K, et al
    Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:872-881.
    

    >> Share

    
    April 2023
74. MOSCHINI M, Necchi A, Briganti A, Montorsi F, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
    

    >> Share

    
    
75. PENG CK, Sung WW
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
    J Urol. 2023;209:676-677.
    

    >> Share

    
    
76. LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
    J Urol. 2023;209:762-772.
    

    >> Share

    
    March 2023
77. STEINBERG RL, O'Donnell MA, Packiam VT
    Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle Invasive Bladder Cancer: The Time is Now.
    J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
    

    >> Share

    
    
78. PENG CK, Sung WW, Chen SL
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share